| SYY |
Report |
Adjusted diluted EPS |
IN-LINE |
pred ~$1.52 vs. cons $1.5115 |
MEDIUM |
| SYY |
Report |
Revenue |
IN-LINE |
pred ~$22.00B vs. cons $21.944B |
MEDIUM |
| SYY |
Report |
U.S. local case growth |
BEAT |
pred ~2.70% vs. cons 2.65% |
MEDIUM |
| SYY |
Guide |
FY2027 adjusted EPS |
BETTER |
guide ~$4.95-$5.05 vs. cons $4.9287 |
LOW |
| SYY |
Guide |
FY2027 revenue |
BETTER |
guide ~$89.0-$90.0B vs. cons $88.465B |
LOW |
| SYY |
Guide |
FY2027 local case growth |
BETTER |
guide ~2.5% vs. cons 2.17% |
LOW |
| SYY |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.5% |
— |
LOW |
| SYY |
Return |
5-day cumulative residual |
+2.5% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — FY2027 estimate revisions |
LOW |